The Jonathan Coleman Lab



Jonathan Coleman
Jonathan Coleman, MD

Our lab is focused on understanding the mechanism of disease recurrence, response to therapies and disease progression of upper tract urothelial cancer, a rare but aggressive disease. To interrogate molecular diversity of the disease, we employ genomics, transcriptomics, metabolomics and tumor immune microenvironment profiling of patient samples as well as patient derived organoids and xenograft models generated in our lab.

Our laboratory has also been developing novel photodynamic therapies for local tumor ablation. The preclinical models are used in support of translational studies for ongoing clinical trials across multiple cancer types. Combination studies of photoablation with immunotherapies are an active area of investigation


Wong NC, Alvim RG, Sjoberg DD, Shingarev R, Power NE, Spaliviero M, Murray KS, Benfante NE, Hakimi AA, Russo P, Coleman JA. Phase III Trial of Intravenous Mannitol Versus Placebo During Nephron-sparing Surgery: Post Hoc Analysis of 3-yr Outcomes. Eur Urol Focus. 2019 Nov;5(6):977-979. doi: 10.1016/j.euf.2019.04.003. Epub 2019 Apr 25. [PMID: ]

View All Publications


Jonathan Coleman

Jonathan Coleman, MD

  • Jonathan Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of urologic malignancies. Ongoing work includes the development of local ablative therapies, their influence on the tumor microenvironment, and implications for therapy response.
  • MD, Cornell University Medical College
[email protected]
Email Address
Office Phone


Kwanghee Kim
Kwanghee Kim

Assistant Attending Biologist

Wesley Yip


Andreas Aulitzky

Research Fellow

Jie Chen

Senior Research Assistant

Fengshen Kuo
Fengshen Kuo

Bioinformatics Engineer III

Peter Reisz

Urology Fellow

Rand Wilcox


Lab Alumni
Kristen Lerch

Research Technician

Karan Nagar

Senior Research Assistant

Jasmine Thomas

Senior Research Technician

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Postdoctoral Fellow

Apply now

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Jonathan Coleman discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures